Patent ID: 8765169
Filing Date: 2014-07-01
Classification: A61K,A61L,A61P,G01N

Abstract:
1. A wound healing composition comprising isolated living dermal fibroblast cells having a wound healing phenotype, characterized in that: (i) the cells of the composition exhibit, at less than 14 days, a 2.08 to 48,200-fold higher level of expression of apolipoprotein D (ApoD); a 694 to 662,000-fold higher level of expression of matrix metalloprotease 2 (MMP2); a 33.7 to 43,300-fold higher level of expression of collagen 3a1 (Coll3a1); and a 20.2 to 121,000-fold higher level of expression of smooth muscle actin (SMA) relative to the expression level of Ribosomal protein L32 (RPL32); or (ii) 75-99% of the cells of the composition have a banding pattern of polymerase chain reaction (PCR) products resulting from differential display identical or similar to that shown in wherein the dermal fibroblast cells are comprised within a fibrin support matrix formed by thrombin-mediated polymerization of a fibrinogen and said dermal fibroblasts followed by incubation of said fibrin support matrix at about 37° C. for about 16-24 hours after formation of said matrix, and wherein said composition has a shelf-life of at least 7 and up to 28 days, when stored at about 2° to 8° C.